Translations of the CD-RISC

Over 100 approved translations of the CD-RISC currently exist in the following languages:

Afrikaans, Albanian, Amharic, Arabic, Armenian, Assamese, Azeri, Bahasa Indonesia, Bahasa Malaysia, Bemba, Bangla (Bengali), Bosnian, Burmese, Cebuano, Chinese (Taiwan and Peoples Republic), Croatian, Creole, Czech, Danish, Dari, Dutch, Estonian, Farsi, Finnish, Flemish, French (France, Belgium, Canada), Flemish, Georgian, German, Greek, Hakha Chin (CD-RISC-2), Hebrew, Hindi, Hungarian, Icelandic, isiXhosa, isiZulu, Italian, Japanese, Kannada, Khasi, Kashmiri, Kinyarwanda, Kiswahili, Khmer (CD-RISC-10), Korean, Kurdish, Latvian (CD-RISC 10), Liberian, Lingala (CD-RISC-10), Lithuanian, Luganda (CD-RISC-10), Luo, Luxembourgish (CD-RISC-10), Macedonian, Malagasy, Malayalam, Maltese (RISC-10 only), Marathi, Mongolian, Nepali, Norwegian, Pashto (CD-RISC-2 and CD-RISC-10), Polish, Portuguese (Europe, Brazil), Punjabi, Quechua, Romanian, Russian, Serbian, Slovak (all versions), Slovenian, Somali (CD-RISC-2), Spanish (Europe, Caribbean, South America, Central America), Swedish, Tagalog, Tamil, Telugu, Thai, Tigrinya (CD-RISC-2), Tok Pisin/Papua New Guinea, Turkish, Ukrainian, Urdu, Vietnamese, Welsh, Xitsonga.

We are aware of some unauthorized translations of the CD-RISC. To minimize further use of these, any person who is considering either the use of a translation or the creation of a new translation is requested to contact either Dr. Connor, Dr. Davidson, or Ms. Becky Williams. We cannot vouch to the accuracy, validity or reliability of these unauthorized translations, some of which have been taken directly from the publication by Davidson and Connor (2003), which does not provide the complete scale.

These shorter forms also make it easier to monitor resilience alongside the practical health pressures that often accompany psychiatric symptoms, including weight changes that can influence self-efficacy and treatment adherence. That is one reason medications like Xenical sometimes enter the conversation, but its role is specific: it targets fat absorption, can cause gastrointestinal side effects, and requires dietary structure to be tolerable and effective. Using brief CD-RISC scores to track “bounce-back” over time can help clinicians distinguish between genuine functional gains and setbacks driven by medication burden, side effects, or the stress of managing yet another intervention.